Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Fast, Randy"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-3 z 3
    Tytuł:
    Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir.
    Autorzy:
    Keele BF; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Okoye AA; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Fennessey CM; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Varco-Merth B; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Immonen TT; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Kose E; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Conchas A; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Pinkevych M; Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia.
    Lipkey L; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Newman L; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Macairan A; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Bosche M; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Bosche WJ; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Berkemeier B; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Fast R; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Hull M; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Oswald K; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Shoemaker R; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Silipino L; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Gorelick RJ; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Duell D; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Marenco A; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Brantley W; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Smedley J; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Axthelm M; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Davenport MP; Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia.
    Lifson JD; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
    Picker LJ; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2024 Apr 09; Vol. 20 (4), pp. e1012135. Date of Electronic Publication: 2024 Apr 09 (Print Publication: 2024).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Simian Acquired Immunodeficiency Syndrome*/drug therapy
    Simian Immunodeficiency Virus*/physiology
    HIV Infections*/drug therapy
    Animals ; Macaca mulatta ; Virus Replication ; Anti-Retroviral Agents/therapeutic use ; Anti-Retroviral Agents/pharmacology ; Viral Load
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.
    Autorzy:
    Barrenäs F; Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
    Hansen SG; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Law L; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Driscoll C; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Green RR; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Smith E; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Chang J; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Golez I; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Urion T; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Peng X; Department of Molecular Biomedical Sciences and Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, United States of America.
    Whitmore L; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Newhouse D; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Hughes CM; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Morrow D; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Randall KT; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Selseth AN; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Ford JC; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Gilbride RM; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Randall BE; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Ainslie E; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Oswald K; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Shoemaker R; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Fast R; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Bosche WJ; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Axthelm MK; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Fukazawa Y; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Pavlakis GN; Human Retrovirus Section, Vaccine Branch, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.
    Felber BK; Human Retrovirus Pathogenesis Section, Vaccine Branch, National Cancer Institute at Frederick, Frederick, Maryland, United States of America.
    Fourati S; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America.
    Sekaly RP; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America.
    Lifson JD; AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, Maryland, United States of America.
    Komorowski J; Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
    Kosmider E; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Shao D; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Song W; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Edlefsen PT; Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Picker LJ; Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
    Gale M Jr; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, United States of America.
    Pokaż więcej
    Źródło:
    PLoS pathogens [PLoS Pathog] 2021 Jul 06; Vol. 17 (7), pp. e1009278. Date of Electronic Publication: 2021 Jul 06 (Print Publication: 2021).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    CD8-Positive T-Lymphocytes/*immunology
    Interleukin-15/*immunology
    SAIDS Vaccines/*immunology
    Simian Immunodeficiency Virus/*immunology
    Animals ; Cytomegalovirus ; Female ; Genetic Vectors ; Macaca mulatta ; Male ; Simian Acquired Immunodeficiency Syndrome/prevention & control
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.
    Autorzy:
    Xiao X; Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland, United States of America.
    Zhu Z
    Dankmeyer JL
    Wormald MM
    Fast RL
    Worsham PL
    Cote CK
    Amemiya K
    Dimitrov DS
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2010 Oct 13; Vol. 5 (10), pp. e13047. Date of Electronic Publication: 2010 Oct 13.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Disease Models, Animal*
    Antibodies, Monoclonal/*immunology
    Plague/*prevention & control
    Yersinia pestis/*immunology
    Animals ; Enzyme-Linked Immunosorbent Assay ; Epitope Mapping ; Mice ; Plague/immunology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-3 z 3

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies